Huge attempts have been made to develop drugs that can control the activity of NF-κB in chronic inflammatory lung diseases, such as the inhibitor of κB kinase (IKK) β inhibitors, but due to the critical role of NF-κB in the host’s defense against pathogens, there are concerns that inhibitors may increase the risk of infection [7]. This evidence concerns the gene NFKB1 and infection.